AU2017217542B2 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators - Google Patents
Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators Download PDFInfo
- Publication number
- AU2017217542B2 AU2017217542B2 AU2017217542A AU2017217542A AU2017217542B2 AU 2017217542 B2 AU2017217542 B2 AU 2017217542B2 AU 2017217542 A AU2017217542 A AU 2017217542A AU 2017217542 A AU2017217542 A AU 2017217542A AU 2017217542 B2 AU2017217542 B2 AU 2017217542B2
- Authority
- AU
- Australia
- Prior art keywords
- triazol
- methoxy
- phenyl
- pyrimidine
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293680P | 2016-02-10 | 2016-02-10 | |
| US62/293,680 | 2016-02-10 | ||
| PCT/US2017/017093 WO2017139428A1 (en) | 2016-02-10 | 2017-02-09 | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017217542A1 AU2017217542A1 (en) | 2018-08-23 |
| AU2017217542B2 true AU2017217542B2 (en) | 2021-06-03 |
Family
ID=58054551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017217542A Ceased AU2017217542B2 (en) | 2016-02-10 | 2017-02-09 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10071988B2 (enExample) |
| EP (1) | EP3414233A1 (enExample) |
| JP (1) | JP6923543B2 (enExample) |
| KR (1) | KR20180108822A (enExample) |
| CN (1) | CN109071488B (enExample) |
| AU (1) | AU2017217542B2 (enExample) |
| BR (1) | BR112018016329A2 (enExample) |
| CA (1) | CA3014314A1 (enExample) |
| EA (1) | EA201891799A1 (enExample) |
| IL (1) | IL261046B (enExample) |
| MA (1) | MA44008A (enExample) |
| MX (1) | MX2018009752A (enExample) |
| SG (1) | SG11201806750WA (enExample) |
| WO (1) | WO2017139428A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| JP6923543B2 (ja) | 2016-02-10 | 2021-08-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
| US11883387B2 (en) | 2018-07-03 | 2024-01-30 | Helmholtz-Zentrum für Infektionsforschung GmbH | PqsR inverse agonists |
| BR112021025136A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| CR20210580A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b |
| WO2020249802A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| WO2020249785A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| WO2021253180A1 (en) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators |
| WO2024077292A2 (en) * | 2022-10-07 | 2024-04-11 | Augusta University Research Institute, Inc. | Synthesis of nsaid conjugates as anti-inflammatory and analgesic agents using the molecular hybridization approach |
| CN115947692B (zh) * | 2022-12-28 | 2024-12-27 | 上海再启生物技术有限公司 | 一种制备2-氯-4-(甲氧基甲基)嘧啶的方法 |
| WO2024208292A1 (zh) * | 2023-04-04 | 2024-10-10 | 江苏亚虹医药科技股份有限公司 | 泛素特异性蛋白酶1抑制剂、其制备方法及其医药用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009118187A1 (en) * | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| AU2003214412A1 (en) | 2002-03-28 | 2003-10-13 | Eisai R & D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| DE10315570A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Triazolderivate |
| EA200601266A1 (ru) * | 2004-02-18 | 2007-02-27 | Астразенека Аб | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| WO2006110724A2 (en) * | 2005-04-11 | 2006-10-19 | Yale University | Method of treating schizophrenia prodrome |
| WO2007115231A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2008145616A1 (en) | 2007-05-25 | 2008-12-04 | Abbott Gmbh & Co. Kg | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
| EP2194045A4 (en) | 2007-08-30 | 2011-09-21 | Takeda Pharmaceutical | Substituted pyrazole derivative |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| CN102171210B (zh) | 2008-08-05 | 2014-04-23 | 第一三共株式会社 | 咪唑并吡啶-2-酮衍生物 |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| ES2466341T3 (es) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
| EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
| EP2408753A4 (en) | 2009-03-20 | 2012-11-07 | Univ Brandeis | COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| US9434743B2 (en) | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| JP6923543B2 (ja) | 2016-02-10 | 2021-08-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
-
2017
- 2017-02-09 JP JP2018541636A patent/JP6923543B2/ja active Active
- 2017-02-09 EA EA201891799A patent/EA201891799A1/ru unknown
- 2017-02-09 AU AU2017217542A patent/AU2017217542B2/en not_active Ceased
- 2017-02-09 US US15/428,710 patent/US10071988B2/en active Active
- 2017-02-09 SG SG11201806750WA patent/SG11201806750WA/en unknown
- 2017-02-09 MX MX2018009752A patent/MX2018009752A/es unknown
- 2017-02-09 KR KR1020187026142A patent/KR20180108822A/ko not_active Withdrawn
- 2017-02-09 BR BR112018016329A patent/BR112018016329A2/pt not_active Application Discontinuation
- 2017-02-09 CA CA3014314A patent/CA3014314A1/en active Pending
- 2017-02-09 CN CN201780022887.6A patent/CN109071488B/zh active Active
- 2017-02-09 WO PCT/US2017/017093 patent/WO2017139428A1/en not_active Ceased
- 2017-02-09 EP EP17705768.4A patent/EP3414233A1/en not_active Withdrawn
- 2017-02-09 MA MA044008A patent/MA44008A/fr unknown
-
2018
- 2018-07-26 US US16/046,332 patent/US10233173B2/en active Active
- 2018-08-08 IL IL261046A patent/IL261046B/en unknown
- 2018-12-31 US US16/237,333 patent/US10766880B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009118187A1 (en) * | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Non-Patent Citations (1)
| Title |
|---|
| STN CAS Online, Chemical Abstracts Registry #1394745-67-5, Entered STN: 18th September 2012 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201806750WA (en) | 2018-09-27 |
| IL261046A (en) | 2019-02-28 |
| JP2019504854A (ja) | 2019-02-21 |
| WO2017139428A1 (en) | 2017-08-17 |
| JP6923543B2 (ja) | 2021-08-18 |
| US20180334451A1 (en) | 2018-11-22 |
| CA3014314A1 (en) | 2017-08-17 |
| US20190135791A1 (en) | 2019-05-09 |
| IL261046B (en) | 2021-09-30 |
| MA44008A (fr) | 2018-12-19 |
| AU2017217542A1 (en) | 2018-08-23 |
| US10233173B2 (en) | 2019-03-19 |
| KR20180108822A (ko) | 2018-10-04 |
| BR112018016329A2 (pt) | 2018-12-18 |
| MX2018009752A (es) | 2019-02-07 |
| US10766880B2 (en) | 2020-09-08 |
| CN109071488B (zh) | 2021-08-13 |
| US20170226089A1 (en) | 2017-08-10 |
| EP3414233A1 (en) | 2018-12-19 |
| US10071988B2 (en) | 2018-09-11 |
| EA201891799A1 (ru) | 2019-02-28 |
| CN109071488A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017217542B2 (en) | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | |
| US11759455B2 (en) | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | |
| US20240317705A1 (en) | Potassium channel modulators | |
| US10377753B2 (en) | Substituted 4-azaindoles and their use as GluN2B receptor modulators | |
| AU2010277588B2 (en) | Pyridine and pyrazine derivatives as protein kinase modulators | |
| US11161846B2 (en) | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | |
| US11530210B2 (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | |
| WO2020144638A1 (en) | Dihydroorotate dehydrogenase inhibitors | |
| EP3544613A1 (en) | Gsk-3 inhibitors | |
| US20220274984A1 (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators | |
| HK40061699A (en) | Dihydroorotate dehydrogenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |